Filing Details
- Accession Number:
- 0001104659-21-134623
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-11-04 21:00:33
- Reporting Period:
- 2021-11-02
- Accepted Time:
- 2021-11-04 21:00:33
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1689375 | Entrada Therapeutics Inc. | TRDA | () | DE |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1425738 | Redmile Group, Llc | One Letterman Drive Building D, Suite D3-300 San Francisco CA 94129 | No | No | Yes | No | |
| 1650527 | Jeremy Green | C/O Redmile Group, Llc One Letterman Drive, Building D #D3-300 San Francisco CA 94129 | No | No | Yes | No | |
| 1838746 | Redmile Biopharma Investments Iii, L.p. | C/O Redmile Group, Llc One Letterman Drive, Building D # D3-300 San Francisco CA 94129 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-11-02 | 954,420 | $0.00 | 954,420 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2021-11-02 | 1,000,000 | $20.00 | 1,954,420 | No | 4 | P | Indirect | See Footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See Footnote |
| No | 4 | P | Indirect | See Footnote |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series B Convertible Preferred Stock | Disposition | 2021-11-02 | 954,420 | $0.00 | 954,420 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect |
Footnotes
- The Series B convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series B convertible preferred stock had no expiration date.
- These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC ("Redmile"), including Redmile Biopharma Investments III, L.P., and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- Reflects number of shares owned as of November 2, 2021.
Billionaire Hedge Funds
